{"owner": "ArrayExpress Uploader", "pop_total": 0, "species": "mouse", "factors": [{"GSM632869": {"DISEASE STATUS": "failing, 6 months of AAC"}}, {"GSM632869": {"DISEASE STATUS": "failing, 6 months of AAC"}}, {"GSM63287": {"DISEASE STATUS": "control"}}, {"GSM63287": {"DISEASE STATUS": "control"}}, {"GSM632877": {"DISEASE STATUS": "6 months of AAC"}}, {"GSM632877": {"DISEASE STATUS": "6 months of AAC"}}], "id": 6287, "ownerprofile_id": "arrayexpress_sid", "platform": 6, "summary_wrapped": "Heart failure is a leading cause of cardiovascular mortality with limited options for treatment. We analyzed whether the anti-ischemic...", "geo_gse_id": "E-GEOD-25766", "owner_profile": "/profile/8773/arrayexpressuploader", "factor_count": 1, "sample_count": 6, "tags": ["heart"], "lastmodified": "Dec.12, 2014", "is_default": false, "geo_gds_id": "", "slug": "cardiac-gene-expression-profiling-of-heart-failure", "geo_id_plat": "E-GEOD-25766_A-AFFY-45", "name": "Cardiac gene expression profiling of heart failure treatment with the anti-ischemic drug ranolazine", "created": "Nov.11, 2014", "summary": "Heart failure is a leading cause of cardiovascular mortality with limited options for treatment. We analyzed whether the anti-ischemic drug ranolazine could retard the progression of heart failure in an experimental model of heart failure induced by 6 months of chronic pressure overload. The study showed that 2 months of ranolazine treatment improved cardiac function of aortic constricted C57BL/6J (B6)  mice with symptoms of heart failure as assessed by echocardiography. The microarray gene expression study of heart tissue from failing hearts relative to ranolazine-treated and healthy control hearts identified heart failure-specific genes that were normalized during treatment with the anti-ischemic drug ranolazine. Microarray gene expression profiling was performed with heart tissue isolated from three study groups: (i) untreated 10 month-old C57BL/6J (B6) mice with heart failure induced by 6 months of abdominal aortic constriction (AAC), (ii) 10 month-old B6 mice with 6 months of AAC and two months of treatment with the anti-ischemic drug ranolazine (200 mg/kg), and (iii) age-matched, untreated, sham-operated B6 control mice.", "source": "http://www.ebi.ac.uk/arrayexpress/experiments/E-GEOD-25766", "sample_source": "http://www.ebi.ac.uk/arrayexpress/experiments/E-GEOD-25766/samples/"}